PeptiStar Inc. is a Japanese contract development and manufacturing organization (CDMO) specializing in peptide and oligonucleotide active pharmaceutical ingredients (APIs). Headquartered in Settsu, Osaka, the company operates a GMP-compliant manufacturing facility for these medium-molecule therapeutics. Founded in 2017 as a joint venture involving PeptiDream Inc., Shionogi & Co., Ltd., and Sekisui Chemical Co., Ltd., it focuses on research, development, manufacturing, and sales of peptide APIs and expanded into nucleic acid drug substances in 2021. In November 2024, Sumitomo Chemical acquired shares through a private placement to strengthen supply capabilities for high-purity guide RNA and integrate related technologies.
Official website: peptistar.com
